Title
Category
Credits
Event date
Cost
Management of Immune Checkpoint Inhibitor-Related Toxicities
  • Management of Immunotherapy-Related Toxicities
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The landscape of cancer care has undergone a dramatic shift, due to the availability and increased use of immunotherapy agents such as immune checkpoint inhibitors (ICIs). As more patients become eligible to receive ICIs, clinicians need to be able to recognize immune-mediated adverse events (irAEs) and remain informed about the most up-to-date strategies for managing these toxicities.
Team-Based Case Review: Oligometastatic Prostate, Non-Small Cell Lung, and Colorectal Cancers
  • Lung Cancers
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The role of metastasis-directed therapy (MDT) for patients with oligometastatic cancer is rapidly evolving, and trials have shown that integrating metastasis-directed therapy into the care of these patients can improve oncologic outcomes including time to disease progression and overall survival.
Smoking Cessation for Patients with Cancer: State of the Evidence
  • Smoking Cessation
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Smoking is not only linked to the development of tobacco-related cancers, but also to the prognosis upon diagnosis and risk of death during treatment. Clinicians must understand the complexity of smoking cessation interventions in this patient population to mitigate smoking-associated risks and improve patient outcomes.
Expansion of Recommendations for Hereditary Cancers
  • Genetic/Familial High-Risk Assessment
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The prevalence of genetic predisposition to cancer is greater than initially appreciated. Due to the increase in multigene testing and the evidence-base surrounding genes and hereditary syndromes associated with cancer, the recommendations in the NCCN Guidelines for Genetic/Familial High-Risk Assessment have expanded and adapted accordingly.
Team-Based Case Review: Hepatocellular Carcinoma
  • Hepatocellular Carcinoma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Hepatocellular carcinoma (HCC) is associated with poor prognosis, and many patients are diagnosed at an advanced stage. It is essential that all patients be evaluated by a multidisciplinary team prior to treatment initiation.
Advances in Treatment of Recurrent Ovarian Cancer and Rare Malignant Germ Cell Tumors
  • Ovarian Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The treatment landscape for ovarian, fallopian tube, and primary peritoneal cancers has significantly evolved in recent years due to new FDA approvals and emerging clinical data on available targeted therapies. Additionally, clinical approach for all uncommon histologies of ovarian cancer including rare malignant germ cell tumors can be variable.
Advances in Head and Neck Cancers: Nasopharyngeal and Oral Cancers
  • Head and Neck Cancers
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Managing and preventing sequelae following surgery, radiation therapy (RT), and systemic therapy (e.g., trismus, pain, lymphedema and muscle spasm of the neck, xerostomia, dysphagia, speech and swallowing problems, dental and jaw decay, depression, peripheral neuropathy, hearing loss, renal failure) requires professionals familiar with head and neck cancers. Limited data are available comparing the efficacy of different chemoradiotherapy regimens for squamous cell carcinoma of the head and neck (SCCHN). Immunotherapy options for recurrent/metastatic nasopharyngeal cancer is a rapidly evolving area of research.
Dental Care for Patients with Cancer: What Oncologists Need to Know
  • Head and Neck Cancers
  • Supportive Care Topics
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Multiple dental issues can arise for patients with cancer throughout the continuum of cancer therapy. Clinicians must be familiar with the potential complications that can arise in the oral cavity from cancer treatment modalities in order to assist in the prevention and treatment of dental toxicities.
Optimizing Patient Outcomes - Targeted Therapies for Thyroid Carcinoma
  • Thyroid Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
05/21/2025
$0.00
Thyroid carcinoma is a rare disease; however, it is the seventh most common cancer diagnosed in those assigned female at birth. Greater attention to rare diseases is needed to improve treatment options in general, and specifically for anaplastic thyroid carcinoma.  Pharmacists can play a role in appropriate treatment selection, monitoring, and modification.
NCCN Tumor Boards: New Approaches to the Management of Resectable Non-Small Cell Lung Cancer
  • Lung Cancers
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
05/22/2025
$0.00
In recent years, several new systemic therapy regimens were approved by the FDA as additional neoadjuvant or adjuvant treatment options for eligible patients with resectable NSCLC and included in the NCCN Guidelines for NSCLC. Clinicians need to be aware of the updated treatment recommendations to ensure optimal outcomes for patients with early-stage NSCLC.

Pages